JP2003531114A - プロテインキナーゼα阻害剤の使用 - Google Patents

プロテインキナーゼα阻害剤の使用

Info

Publication number
JP2003531114A
JP2003531114A JP2001556489A JP2001556489A JP2003531114A JP 2003531114 A JP2003531114 A JP 2003531114A JP 2001556489 A JP2001556489 A JP 2001556489A JP 2001556489 A JP2001556489 A JP 2001556489A JP 2003531114 A JP2003531114 A JP 2003531114A
Authority
JP
Japan
Prior art keywords
pkiα
agonist
antagonist
beta
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001556489A
Other languages
English (en)
Japanese (ja)
Inventor
クネル，ラルフ
Original Assignee
シエーリング アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シエーリング アクチエンゲゼルシャフト filed Critical シエーリング アクチエンゲゼルシャフト
Publication of JP2003531114A publication Critical patent/JP2003531114A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
JP2001556489A 2000-02-03 2001-01-31 プロテインキナーゼα阻害剤の使用 Pending JP2003531114A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10004858.7 2000-02-03
DE10004858A DE10004858A1 (de) 2000-02-03 2000-02-03 Verwendung von Proteinkinase-Inhibitor-alpha
PCT/EP2001/001002 WO2001056590A2 (de) 2000-02-03 2001-01-31 Verwendung von proteinkinase-inhibitor-alpha

Publications (1)

Publication Number Publication Date
JP2003531114A true JP2003531114A (ja) 2003-10-21

Family

ID=7629772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001556489A Pending JP2003531114A (ja) 2000-02-03 2001-01-31 プロテインキナーゼα阻害剤の使用

Country Status (5)

Country Link
EP (1) EP1253931A2 (de)
JP (1) JP2003531114A (de)
AU (1) AU2001233723A1 (de)
DE (1) DE10004858A1 (de)
WO (1) WO2001056590A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014001243A (ja) * 2006-08-01 2014-01-09 Board Of Regents The Univ Of Texas System ベータミオシン重鎖の発現を活性化するマイクロｒｎａの同定

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
US9974759B2 (en) 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
WO1998022122A1 (en) * 1996-11-21 1998-05-28 Promega Corporation Alkyl peptide amides and applications
US6203776B1 (en) * 1997-04-03 2001-03-20 University Technology Corporation Method for identifying adrenergic receptor antagonists having good tolerability

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014001243A (ja) * 2006-08-01 2014-01-09 Board Of Regents The Univ Of Texas System ベータミオシン重鎖の発現を活性化するマイクロｒｎａの同定

Also Published As

Publication number Publication date
WO2001056590A2 (de) 2001-08-09
DE10004858A1 (de) 2001-08-16
AU2001233723A1 (en) 2001-08-14
WO2001056590A3 (de) 2002-06-20
EP1253931A2 (de) 2002-11-06

Similar Documents

Publication Publication Date Title
DE60202727T2 (de) Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie
CA2458798C (en) Method for reducing hypertension and heart failure
JP5498918B2 (ja) 低酸素誘導性因子（ＨＩＦ）−αの安定化
CA2514948C (fr) Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament
AU2002313700A1 (en) Method for reducing hypertension and heart failure
US20090191194A1 (en) Inhibition of protein kinase c alpha for the treatment of cardiovascular diseases
KR100902799B1 (ko) 키마제 저해제 및 ａｃｅ 저해제를 유효성분으로 함유하는약제
JP2002534360A (ja) 疾病治療用製剤及びその使用方法
JP2007532483A (ja) 心筋梗塞の治療方法
CA2881990C (en) Use of probenecid to treat acute decompensated heart failure
JP2003531114A (ja) プロテインキナーゼα阻害剤の使用
US20210386744A1 (en) Sildenafil for use in the treatment of osteoarthritis
US20140296143A1 (en) Angiotensin-(1-7) As A Chemoprevention Agent
US20020103117A1 (en) Use of protein kinase-inhibitor-alpha
JP2001518062A (ja) 肺繊維症の治療
IL263240A (en) Methods and preparations for the treatment of secretory disorders
US20040224907A1 (en) Compositions and methods for reversal of drug resistance
WO2003047624A1 (en) Cell migration inhibitor
AU2003215446B2 (en) Use of C5a receptor antagonist in the treatment of fibrosis
EP1605262A1 (de) Methode zur Idenfitikation von Inhibitoren der Herzhypertrophie
Crawford Effects of angiotensin II on fibronectin regulation during cardiac fibrosis in the rat
JPWO2003020312A1 (ja) 虚血性心不全治療剤
Physiologically et al. Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin–angiotensin system
Isoniazid Conditioning Convulsions MED (mg/kg) Latency (min)